Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Jun;95(6):2777–2782. doi: 10.1172/JCI117981

2'3'-Dideoxycytidine-induced thymic lymphoma correlates with species-specific suppression of a subpopulation of primitive hematopoietic progenitor cells in mouse but not rat or human bone marrow.

R D Irons 1, A T Le 1, D B Som 1, W S Stillman 1
PMCID: PMC295962  PMID: 7539460

Abstract

The nucleoside analogue, 2',3'-dideoxycytidine (ddC), is a potent inhibitor of HIV replication, and AIDS patients receiving ddC experience clinical improvement without significant hematologic toxicity. Repeated ddC administration (1,000 mg/kg per day) for 13 wk produces an increased incidence of thymic lymphoma in B6C3F1 mice. Previous studies reveal a common link between chemically induced and genetically associated models of mouse thymic lymphoma that involves a defect in a subpopulation of primitive hematopoietic progenitor cells. This defect is characterized by suppression of a subpopulation of IL-3-responsive cells and ablation of stem cell factor synergy with GM-CSF. The present study was undertaken to ascertain whether ddC produces the same pattern of bone marrow toxicity in mice, and whether this effect is observed in rat and human bone marrow. ddC exposure in vivo and in vitro produced a select suppression of murine CFU identical to that previously described for other models of mouse thymic lymphoma. In contrast, this selective CFU suppression was not observed in rat and human bone marrow or in CD34+ cells. These studies suggest that the mouse may not be a good predictive model for ddC hematotoxicity in humans and that susceptibility to the development of thymic lymphoma may be unique to the mouse.

Full text

PDF
2777

Images in this article

2779Image
on p.2779

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balzarini J., Pauwels R., Baba M., Herdewijn P., de Clercq E., Broder S., Johns D. G. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol. 1988 Mar 1;37(5):897–903. doi: 10.1016/0006-2952(88)90178-5. [DOI] [PubMed] [Google Scholar]
  2. Chabot B., Stephenson D. A., Chapman V. M., Besmer P., Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 1988 Sep 1;335(6185):88–89. doi: 10.1038/335088a0. [DOI] [PubMed] [Google Scholar]
  3. Colagiovanni D. B., Stillman W. S., Irons R. D. Chemical suppression of a subpopulation of primitive hematopoietic progenitor cells: 1,3-butadiene produces a hematopoietic defect similar to steel or white spotted mutations in mice. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2803–2806. doi: 10.1073/pnas.90.7.2803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dorr F. A., Coltman C. A., Jr Second cancers following antineoplastic therapy. Curr Probl Cancer. 1985 Feb;9(2):1–43. doi: 10.1016/s0147-0272(85)80033-7. [DOI] [PubMed] [Google Scholar]
  5. HARAN-GHERA N., KAPLAN H. S. SIGNIFICANCE OF THYMUS AND MARROW INJURY IN URETHAN LEUKEMOGENESIS. Cancer Res. 1964 Dec;24:1926–1931. [PubMed] [Google Scholar]
  6. Haran-Ghera N., Peled A. Induction of leukemia in mice by irradiation and radiation leukemia virus variants. Adv Cancer Res. 1979;30:45–87. doi: 10.1016/s0065-230x(08)60894-5. [DOI] [PubMed] [Google Scholar]
  7. Haran-Ghera N. Spontaneous and induced preleukemia cells in C57BL/6 mice:brief communication. J Natl Cancer Inst. 1978 Mar;60(3):707–710. doi: 10.1093/jnci/60.3.707. [DOI] [PubMed] [Google Scholar]
  8. Irons R. D., Smith C. N., Stillman W. S., Shah R. S., Steinhagen W. H., Leiderman L. J. Macrocytic-megaloblastic anemia in male B6C3F1 mice following chronic exposure to 1,3-butadiene. Toxicol Appl Pharmacol. 1986 Mar 30;83(1):95–100. doi: 10.1016/0041-008x(86)90326-1. [DOI] [PubMed] [Google Scholar]
  9. Irons R. D., Smith C. N., Stillman W. S., Shah R. S., Steinhagen W. H., Leiderman L. J. Macrocytic-megaloblastic anemia in male NIH Swiss mice following repeated exposure to 1,3-butadiene. Toxicol Appl Pharmacol. 1986 Sep 30;85(3):450–455. doi: 10.1016/0041-008x(86)90352-2. [DOI] [PubMed] [Google Scholar]
  10. Kaplan H. S. On the natural history of the murine leukemias: presidential address. Cancer Res. 1967 Aug;27(8):1325–1340. [PubMed] [Google Scholar]
  11. Leary A. G., Zeng H. Q., Clark S. C., Ogawa M. Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4013–4017. doi: 10.1073/pnas.89.9.4013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mitsuya H., Jarrett R. F., Matsukura M., Di Marzo Veronese F., DeVico A. L., Sarngadharan M. G., Johns D. G., Reitz M. S., Broder S. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2033–2037. doi: 10.1073/pnas.84.7.2033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Muto M., Kubo E., Sado T. Cellular events during radiation-induced thymic leukemogenesis in mice: abnormal T cell differentiation in the thymus and defect of thymocyte precursors in the bone marrow after split-dose irradiation. J Immunol. 1985 Mar;134(3):2026–2031. [PubMed] [Google Scholar]
  14. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 1993 Jun 1;81(11):2844–2853. [PubMed] [Google Scholar]
  15. Owen P. E., Glaister J. R., Gaunt I. F., Pullinger D. H. Inhalation toxicity studies with 1,3-butadiene. 3. Two year toxicity/carcinogenicity study in rats. Am Ind Hyg Assoc J. 1987 May;48(5):407–413. doi: 10.1080/15298668791384959. [DOI] [PubMed] [Google Scholar]
  16. Owen P. E., Glaister J. R. Inhalation toxicity and carcinogenicity of 1,3-butadiene in Sprague-Dawley rats. Environ Health Perspect. 1990 Jun;86:19–25. doi: 10.1289/ehp.908619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  18. Russell E. S. Hereditary anemias of the mouse: a review for geneticists. Adv Genet. 1979;20:357–459. [PubMed] [Google Scholar]
  19. Sutherland H. J., Hogge D. E., Cook D., Eaves C. J. Alternative mechanisms with and without steel factor support primitive human hematopoiesis. Blood. 1993 Mar 15;81(6):1465–1470. [PubMed] [Google Scholar]
  20. Sutherland H. J., Lansdorp P. M., Henkelman D. H., Eaves A. C., Eaves C. J. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci U S A. 1990 May;87(9):3584–3588. doi: 10.1073/pnas.87.9.3584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Waqar M. A., Evans M. J., Manly K. F., Hughes R. G., Huberman J. A. Effects of 2',3'-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol. 1984 Nov;121(2):402–408. doi: 10.1002/jcp.1041210218. [DOI] [PubMed] [Google Scholar]
  22. Williams D. E., Eisenman J., Baird A., Rauch C., Van Ness K., March C. J., Park L. S., Martin U., Mochizuki D. Y., Boswell H. S. Identification of a ligand for the c-kit proto-oncogene. Cell. 1990 Oct 5;63(1):167–174. doi: 10.1016/0092-8674(90)90297-r. [DOI] [PubMed] [Google Scholar]
  23. Witte O. N. Steel locus defines new multipotent growth factor. Cell. 1990 Oct 5;63(1):5–6. doi: 10.1016/0092-8674(90)90280-r. [DOI] [PubMed] [Google Scholar]
  24. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES